Parasetamol

PreclinicalSmall molecule

GGiresun University

Parasetamol is one of 30 small molecule programs targeting Hysterectomy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HysterectomyActive, not recruiting

HysterectomyPreclinical

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Hysterectomy

#DrugCompanyPhaseTrials

Cervidil

Pfizer

Phase 3

1 2

Arcoxia

Novartis

Phase 3

1 3

Elavil

AstraZeneca

Phase 3

1 4

Tylenol

KKenvue Brands

Phase 3

4 5

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

3 6

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 7

Ketalar

AAultman Health Foundation

Phase 3

1 8

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 3

1 9

Spravato

WWim Janssens

Phase 2

1 10

Depot Medroxyprogesterone Acetate

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hysterectomy1 trial

Preemptive Analgesia in Laparoscopic Hysterectomy

Not yet recruiting·GGiresun University··NCT07401927·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Parasetamol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Parasetamol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Parasetamol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Giresun University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGiresun University

Parasetamol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hysterectomy1 trial

References

Drug Info

Quick Facts

Related News